MULTI DEFENDER VONTI - BIOGEN IDEC/BIONTECH ADR/MODERNA | Market Closed - Swiss Exchange 16:20:00 08/05/2024 BST | ||
| 99.9 CHF | +0.50% |
|
| Current month | +3.10% | ||
| 1 month | +3.63% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/05/24 | 99.9 | +0.50% | 0 |
| 07/05/24 | 99.4 | +0.10% | 0 |
| 06/05/24 | 99.3 | +0.30% | 0 |
| 03/05/24 | 99 | +1.02% | 0 |
Delayed Quote Swiss Exchange
Last update May 08, 2024 at 04:20 pm
More quotesStatic data
| Product type | Reverse Convertibles |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| RMAVJV | |
| ISIN | CH1280438552 |
| Date issued | 20/07/2023 |
| Strike | 274.7 $ |
| Maturity | 22/07/2024 (72 Days) |
| Parity | 0.27 : 1 |
| Emission price | 100 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 99.9 CHF |
|---|---|
| Lowest since issue | 74.4 CHF |
| Spread | 8 CHF |
| Spread % | 0.80% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
221.5
USD
Average target price
285.9
USD
Spread / Average Target
+29.08%
- Stock Market
- Certificates
- RMAVJV Certificat
